Related Experiment Video

Updated: Aug 15, 2026

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

Dobesilate is an angiogenesis inhibitor

Pedro Cuevas1, I Sanchez, R M Lozano

  • 1Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid, Spain. pedro.cuevas@hrc.es

European Journal of Medical Research
|September 27, 2005
PubMed

Insights

Dobesilate, an oral medication, significantly inhibited blood vessel formation in a mouse model. This suggests its potential as a novel antiangiogenic therapy for various cancers and other angiogenesis-dependent diseases.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Aberrant angiogenesis fuels tumor progression in solid tumors and hematological malignancies.
  • Antiangiogenic therapy presents a promising strategy for treating these diseases.
  • Dobesilate is an established oral agent for managing vascular issues in diabetic retinopathy.

Purpose of the Study:

  • To investigate the antiangiogenic potential of dobesilate.
  • To determine if dobesilate interferes with the process of neovascularization.
  • To explore dobesilate as a therapeutic agent for angiogenesis-dependent diseases.

Main Methods:

  • A mouse gelatine sponge assay was employed to assess angiogenesis.
  • Acidic fibroblast growth factor (aFGF) was used as an inducer of neovascularization.
  • The effect of dobesilate on vessel ingrowth was quantified in vivo.

Main Results:

  • Dobesilate demonstrated a remarkable reduction in vessel ingrowth within aFGF-containing sponges.
  • The compound effectively inhibited neovascularization induced by aFGF in the mouse model.
  • Quantitative analysis confirmed the antiangiogenic effect of dobesilate.

Conclusions:

  • Dobesilate exhibits significant antiangiogenic properties.
  • These findings support the potential of dobesilate as a therapeutic agent for angiogenesis-dependent diseases.
  • Further research into dobesilate for treating FGF-mediated angiogenesis-related conditions is warranted.

More Related Videos

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...